Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Promising phase I data on CAL-101 in hematological malignancies disclosed

Dec. 24, 2010

FBS-0701 is safe in phase Ib study in subjects with iron overload, phase II trial under way

Dec. 23, 2010

New class of toluidine sulfonamides set to enter clinical testing for the treatment of MM

Dec. 23, 2010

Preclinical data suggest NXD-30001 may hold promise to treat ALS

Dec. 22, 2010

LY-2784544 inhibits V617F-mutant JAK-2 signaling and advances through clinical development

Dec. 22, 2010

Acceleron Pharma's ACE-536 increases red blood cells in vivo

Dec. 22, 2010

MRx-102 shows promise in models of AML

Dec. 21, 2010

NS-018 preferentially targets V617F-mutant JAK2

Dec. 21, 2010

Clinical and preclinical data presented on GDC-0941/T-DM1 in HER2+ breast cancer

Dec. 21, 2010

Panobinostat/capecitabine/lapatinib combination is safe in HER2+ breast cancer

Dec. 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 22, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
CC-3 antibody shows antitumoral activity in penile cancer
BioWorld Science
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...